用逆转录－多聚酶链反应检测肾癌mdr1基因的表达  

Expression of mdrl messenger RNA in human renal cell carcinomas

作　　者：孔祥田[1] 夏同礼[1] 顾方六[1] 刘翠玲[1] 宫恩聪[1] 邓方明[1] 郭应禄[1] 

机构地区：[1]北京医科大学第一医院,北京医科大学基因诊断研究中心

出　　处：《中华泌尿外科杂志》1996年第6期330-332,共3页Chinese Journal of Urology

摘　　要：用逆转录－多聚酶链反应（ＲＴ－ＰＣＲ）技术研究了２例正常肾、１８例原发性肾癌和１例肾盂癌ｍｄｒｌｍＲＮＡ表达状况，结果显示２例正常肾和１５例（８３．３％）肾癌表达ｍｄｒｌｍＲＮＡ基因，另３例肾癌和１例肾盂癌无此基因表达。ｍｄｒｌ基因的表达与肾癌的分级无关（Ｐ＝０．５１）。原发性肾癌ｍｄｒｌ基因的高表达奠定了肾癌内在性耐药的基础。比较不同的基因检测手段显示ＲＴ－ＰＣＲ是简便、快速、灵敏、特异的检测ｍｄｒｌ基因的方法，适于推广。The expression of mdrl mRNA was studied in 2 normal kidneys,18 renal cell carcinomas(RCC)and 1 transitional cell carcinoma of renal pelvis by reverse transcription-polymerase chain reaction(RT-PCR).The results showed that mdrl gene was expressed in all the 2 normal kidneys and in 83.3%(15/18)of RCC while no mdrl gene was detected in the other 3 RCC and 1 pelvic tumor.No correlation was found statistically between the expression of mdrl gene and the grade of RCCs(P=0.51),The high expression of mdrl gene in primary RCC might be the causative factor of its intrinsic drug resistance.RT-PCR was a sensitive,specific and rapid technique in the detection of mdrl gene for clinical specimens.

关 键 词：肾肿瘤 癌 药物耐受性 基因 聚合酶链反应 mdrl 

分 类 号：R737.110.3[医药卫生—肿瘤] R730.45[医药卫生—临床医学]